CeMines公司推出发现肺癌的血液检查方法

一种微创分子血液检查方法能够帮助医生检查和诊断肺癌。这项检查获得了CE标记，将使用CellCorrect KvA-40实验室试剂盒的商标在欧洲上市。

根据CeMines公司(Golden, CO, USA)的说法，这种新型检测方法并不十分昂贵，能够检测血液中自身免疫的病变和与疾病相关的抗体，这些抗体主要是免疫系统产生的。CeMines称这种技术为分子指纹图谱。

该公司已经开展全球患者的临床研究，以证实特异性指标的一致性，这些指标已经被证实能够反应癌症的分化和特征。CeMines使用正在申请的分析复杂生物资料的应用软件用于生物指标的分析，并使用特异性模式识别运算法则。这些资料十分便于阅读评分，不需要医生的主观解释。

Blood Test for Lung Cancer
 
A new minimally invasive molecular blood test is designed to help doctors detect and diagnose lung cancer. The test has received the CE Mark and will be marketed in Europe under the brand name CellCorrect KvA-40 lab kit.

The new test is an inexpensive way to detect altered autoimmunity and associated patterns of disease-related autoantibodies in the bloodstream that are produced by the immune system, according to the test’s developer, CeMines, Inc. (Golden, CO, USA). CeMines calls its technology Molecular FingerPrinting.

The company has conducted international patient studies that demonstrated consistent patterns of specific biomarkers that have proven their utility as viable composite biomarkers able to differentiate and characterize cancer. CeMines uses a patent-pending bioinformatics application for biomarker analysis, followed by specific pattern-recognition algorithms. The data are presented in an easy-to-read score that does not require subjective interpretation by doctors.